Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127868371 | 12786837 | 1 | I | 20120901 | 0 | 20160927 | 20160927 | DIR | US-FDA-351659 | FDA-CTU | 76.00 | YR | M | N | 85.50000 | KG | 20160927 | N | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127868371 | 12786837 | 1 | PS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Oral | N | D | 0 | BID | ||||||||
| 127868371 | 12786837 | 3 | C | NAPROXEN. | NAPROXEN | 1 | 0 | ||||||||||||
| 127868371 | 12786837 | 5 | C | PROPRANOLOL | PROPRANOLOLPROPRANOLOL HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127868371 | 12786837 | 7 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | 0 | ||||||||||||
| 127868371 | 12786837 | 9 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127868371 | 12786837 | 1 | Ingrowing nail |
| 127868371 | 12786837 | 1 | Peripheral swelling |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127868371 | 12786837 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127868371 | 12786837 | Arthralgia | |
| 127868371 | 12786837 | Neuropathy peripheral | |
| 127868371 | 12786837 | Tendonitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |